Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5942944 | 0.84 | HAO1 (0.54) | HAO1KDM4EMEN1KMT2AEGLN1 | |
| SCHEMBL16838788 | 0.84 | NPBWR1 (0.45) | HAO1KDM4EMEN1KMT2AEGLN1 | |
| SCHEMBL16761850 | 0.80 | ALDH1A1 (0.56) | HAO1KDM4EMEN1KMT2AEGLN1 | |
| SCHEMBL16838785 | 0.77 | HAO1 (0.49) | HAO1KDM4EMEN1KMT2APOLB | |
| SCHEMBL6325952 | 0.76 | KDM4E (0.69) | KDM4EMEN1KMT2ATHRBMMP13 | |
| SCHEMBL16761723 | 0.74 | ALDH1A1 (0.64) | HAO1KDM4EEGLN1MAPTPOLB | |
| SCHEMBL31225142 | 0.74 | KDM4E (0.56) | HAO1KDM4EMEN1KMT2APOLB | |
| SCHEMBL15055157 | 0.74 | KDM4E (0.56) | HAO1KDM4EMEN1KMT2APOLB | |
| SCHEMBL16023927 | 0.74 | PTGS1 (0.41) | HAO1KDM4EMEN1KMT2AEGLN1 | |
| SCHEMBL21656857 | 0.73 | MAPT (0.48) | EGLN1MAPTPOLBL3MBTL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3083606-B1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-2964639-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-3293184-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | Purdue Pharma L.P. (US) | 2018-03-14 | — | — | EP | disclosed |
| US-9745287-B2 | Pyrimidines and use thereof | PURDUE PHARMA L.P. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745287-B2 | Pyrimidines and use thereof | PURDUE PHARMA L.P. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2017-07-27 | — | — | US | disclosed |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2017-07-27 | — | — | US | disclosed |
| US-9637458-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. | 2017-05-02 | — | — | US | disclosed |
| US-9637458-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. | 2017-05-02 | — | — | US | disclosed |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. | 2016-11-17 | — | — | US | disclosed |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. | 2016-11-17 | — | — | US | disclosed |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| WO-2015094443-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014135955-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | CACNA1A, TRPV1, TRPA1 | HAO1 3256/4885KDM4E 2252/4885MEN1 3827/4885 |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | CACNA1A, TRPV1, TRPA1 | HAO1 3213/4885KDM4E 2154/4885MEN1 3846/4885 |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | ADORA2B, P2RX2, P2RX3 | HAO1 1964/4885KDM4E 3153/4885MEN1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.